research Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
Semaglutide helps obese PCOS patients lose weight and improve health.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Alopecia and Semaglutide: Connecting the Dots for Patient Safety
Semaglutide may cause hair loss, but more research is needed to confirm this.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research Semaglutide and the Skin: An Overview of Current Evidence
Semaglutide may help some skin disorders but can also cause skin issues.
research Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
A rash from semaglutide may be due to propylene glycol, not the drug itself.
research 53028 Semaglutide and Hair Loss: A Real-World Analysis
Semaglutide does not significantly increase the risk of hair loss.
research Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report
Semaglutide may worsen eating disorders in vulnerable individuals.
research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
research Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions
Combining lifestyle changes with personalized medication is crucial for better managing obesity in PCOS.
research Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
Hair loss from weight-loss treatments is usually temporary and reversible.
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
Newer GLP-1 drugs like semaglutide may cause hair loss.
research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
research Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
Weight-loss drugs are not linked to suicidal thoughts.
research Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
The effect of GLP-1 RAs on erectile function is unclear and needs more research.
research Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
Individualized treatments may help manage Dercum's disease symptoms.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Farmácia Avenida Brasil, Porto
Community pharmacies and pharmacists play a crucial role in improving community health.
research A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
research EFFECTS OF LIRAGLUTIDE ON VISCERAL ADIPOSITY INDEX IN WOMAN OF REPRODUCTIVE AGE WITH PREDIABETES
Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.
research Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Combining liraglutide and metformin helps obese women with PCOS who didn't lose weight on metformin alone to lose more weight.
research Bicalutamide
research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
GLP-1 agonists may help treat certain skin conditions.
research Repurposing existing drugs for COVID-19: an endocrinology perspective
Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
research Metabolic syndrome — a new definition and management guidelines
New guidelines stress early diagnosis and lifestyle changes to manage metabolic syndrome and prevent complications.